Enzolytics Inc (ENZC)

[falon]

Press Release Highlights:


The Extension is the fifth of ten one-month extensions permitted under Sagaliam's governing documents and provides the Company with additional time to complete its business combination.

Now, after almost two and a half years, with planned clinical trials and studies, the Company sees this as the right time to align the talents in the Company to focus on successful advancement of the distinctive technologies within Enzolytics.

Our AI platform and the collaboration we have with Samsung Biologics will accelerate our progress. Since the steps from early discovery to IND studies are identical, we can move ahead rapidly with production of multiple Monoclonal Antibodies."

The Company plans to create an Artificial Intelligence division to develop drug discovery and development strategies. Dr. Bischof said, "Large pharmaceutical companies are creating internal algorithms and partnering with or acquiring new companies to use AI to increase their portfolios and pipelines. With an increased focus on AI-empowered Drug Discovery Platforms that allow the discovery of multiple drugs with multiple targets and applications, we continue to consider collaborations with our AI platform.

In addition, we are creating a strong IP portfolio for multiple infectious diseases covering diagnostics, therapeutics, and vaccines for these viruses. Strategically, we are focused on meeting milestones and licensing each of these assets. The SPAC agreement allows us to move forward with multiple Monoclonal Antibodies simultaneously, bringing significant value to our shareholders."